alg-097558
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 4, 2023 (NCT05840952)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06945276 | Phase 1 | May 13, 2025 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06698549 | Phase 1 | Jan 31, 2025 | Aligos Therapeutics, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06568861 | Phase 1 | Sep 30, 2024 | Aligos Therapeutics, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05840952 | Phase 1 | Jul 4, 2023 | Aligos Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aligos Therapeutics | For profit | 3 | 3 | 1 | 2023 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1